Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

First Houston patient treated with FDA-approved liquid material for brain aneurysm

A 68-year-old woman became the first patient in Houston to have her brain aneurysm treated with a recently FDA-approved liquid material instead of traditional open skull surgery or platinum coils.

18 Jan 2010

FDA extends Tarceva's sNDA review period

OSI Pharmaceuticals, Inc. and Genentech, Inc., a wholly owned member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for Tarceva® (erlotinib) as a first-line maintenance therapy in advanced non-small cell lung cancer (NSCLC) by an additional 90 days.

18 Jan 2010

Safety concerns of acetaminophen

The pain reliever acetaminophen is one of the safest and most effective drugs on the market. It's often recommended instead of aspirin as a day-to-day pain reliever because it's much easier on the stomach than other over-the-counter options and is considered safe when taken properly.

18 Jan 2010

FDA grants orphan drug exclusivity approval for Octapharma AG's wilate

Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).

18 Jan 2010

BDSI to discuss planned BEMA Granisetron IND with the FDA

BioDelivery Sciences International, Inc. announced that the company has been granted a meeting with the U.S. Food and Drug Administration (FDA) to discuss the planned Investigational New Drug (IND) application for BDSI’s antiemetic (anti-nausea and vomiting) product candidate, BEMA Granisetron. The meeting will take place on March 17, 2010. The company will discuss with the FDA clinical development and regulatory plans for BEMA Granisetron, which is anticipated to enter Phase 1 studies in the second quarter of 2010.

13 Jan 2010

Scientists identify fast-acting compound to improve cognitive function impairments

A fast-acting compound that appears to improve cognitive function impairments in mice similar to those found in patients with progressive Alzheimer's disease has been identified by scientists at Wake Forest University School of Medicine and the Vanderbilt University Medical Center Program in Drug Discovery.

13 Jan 2010

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

EKR Therapeutics, Inc., a specialty pharmaceutical company commercializing acute-care hospital products, today said that interim study data1 demonstrate that Cardene® I.V. (nicardipine hydrochloride) is significantly more effective than intravenous labetalol for the management of blood pressure (BP) in stroke patients.

12 Jan 2010

Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA

MAP Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that a second pivotal efficacy study is not required for the Company's LEVADEX(TM) new drug application (NDA) submission for the acute treatment of migraine. The Company announced in May 2009 that the efficacy portion of its Phase 3 FREEDOM-301 clinical study of LEVADEX met all four primary endpoints. The Company had previously anticipated initiating a second pivotal efficacy study in the first quarter of 2010.

12 Jan 2010

A.P. Pharma regains compliance for continued listing on Nasdaq Capital Market

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1).

11 Jan 2010

A.P. Pharma receives final milestone payment of $2.5M from Paul Capital Healthcare

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced it has received the final milestone payment of $2.5 million from an affiliate of Paul Capital Healthcare.

11 Jan 2010

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Ask anyone who suffers from migraine headaches what they do when they're having an attack, and you're likely to hear "go into a dark room." And although it's long been known that light makes migraines worse, the reason why has been unclear.

11 Jan 2010

Sciele Pharma announces the U.S. availability of Adrenaclick

Sciele Pharma, Inc., a Shionogi company, today announced the U.S. availability of Adrenaclick™, a single-dose, epinephrine auto-injector for the emergency treatment for severe allergic reactions (Type I) such as anaphylaxis.

8 Jan 2010

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Following the results of the Angus Reid Strategies and the Applied Health Research Centre at Toronto's St. Michael's Hospital survey conducted on behalf of the Canadian Partnership Against Cancer finding that the majority of Canadians have a good understanding of the benefits of colorectal cancer screening, but are not taking action to get screened, the Colorectal Cancer Association of Canada ("CCAC") is doubling its efforts in 2010 to convince Canadians that they must be more proactive concerning their health and the onset of colorectal cancer.

7 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

Texas Mutual Insurance offers tips to prevent H1N1 flu

Flu season peaks in January and February. For adults, the workplace is the most common place to catch the flu.

7 Jan 2010

CDC and AAFP recommend whooping cough vaccine for adults and adolescents

Many people may think of whooping cough as a disease of the past -- something eradicated generations ago. However, the number of cases reported by the Centers for Disease Control and Prevention (CDC) indicate that whooping cough (pertussis) is still very much a public health concern; health experts estimate that up to 600,000 cases occur each year in adults alone. In fact, whooping cough cases are on the rise in San Diego

6 Jan 2010

VELCADE sNDA receives FDA approval

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The VISTA trial examined the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

5 Jan 2010

Health risks of wooden pallet shipping platforms, call for Congress and FDA regulation

The expanded recall of TYLENOL Arthritis pain reliever is fresh evidence of the need for Congress and the FDA to regulate wood pallets used to transport food and pharmaceuticals in the United States because of the dangers they pose to human health.

4 Jan 2010

Pfizer provides update on Prevnar 13

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has not yet completed its review of the Biologics License Application (BLA) for Prevnar 13™, (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), the Company’s candidate 13-valent pneumococcal conjugate vaccine.

31 Dec 2009

Young people more likely to catch swine flu from an infected person in their household

Young people aged under 18 years are more likely than adults to catch swine flu from an infected person in their household, according to a new study published today in the New England Journal of Medicine.

30 Dec 2009

Vomiting News and Research

Further Reading

First Houston patient treated with FDA-approved liquid material for brain aneurysm

FDA extends Tarceva's sNDA review period

Safety concerns of acetaminophen

FDA grants orphan drug exclusivity approval for Octapharma AG's wilate

BDSI to discuss planned BEMA Granisetron IND with the FDA

Scientists identify fast-acting compound to improve cognitive function impairments

Cardene I.V. more effective than intravenous labetalol for BP management in acute stroke patients

Second pivotal efficacy study not required for MAP Pharmaceuticals' LEVADEX NDA

A.P. Pharma regains compliance for continued listing on Nasdaq Capital Market

A.P. Pharma receives final milestone payment of $2.5M from Paul Capital Healthcare

BIDMC scientists identify new pathway to address the problem of photophobia during migraines

Sciele Pharma announces the U.S. availability of Adrenaclick

CCAC doubles its efforts to convince Canadians to prevent colorectal cancer

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Texas Mutual Insurance offers tips to prevent H1N1 flu

CDC and AAFP recommend whooping cough vaccine for adults and adolescents

VELCADE sNDA receives FDA approval

Health risks of wooden pallet shipping platforms, call for Congress and FDA regulation

Pfizer provides update on Prevnar 13

Young people more likely to catch swine flu from an infected person in their household

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News